Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
9.44
-0.12 (-1.26%)
At close: May 16, 2025, 4:00 PM
9.25
-0.19 (-2.01%)
After-hours: May 16, 2025, 5:44 PM EDT
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $17.36M in the twelve months ending March 31, 2025, down -35.92% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$17.36M
Revenue Growth
-35.92%
P/S Ratio
21.36
Revenue / Employee
$108,522
Employees
160
Market Cap
431.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CAPR News
- 2 days ago - Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 10 days ago - Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewsWire
- 11 days ago - US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
- 11 days ago - Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy - GlobeNewsWire
- 2 months ago - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - PRNewsWire